Lipocine Inc. (LPCN)

Sorry, no known transcripts

Recent filings

Lipocine Announces Trial Date In Lipocine’S Infringement Lawsuit Against Clarus - Aug. 27, 2019

Lipocine Inc. Just Filed Its Quarterly Report:     ... - Aug. 7, 2019

Lipocine Announces Second Quarter 2019 Financial And Operational Results - Aug. 7, 2019

Current report, items 7.01, 8.01, and 9.01 - July 23, 2019

Lipocine Set To Join Russell Microcap® Index - June 25, 2019

Departure of Directors or Certain - June 24, 2019

Lipocine Inc. director was just granted 10,000 options - June 14, 2019

Lipocine Inc. director was just granted 10,000 options - June 14, 2019

Lipocine Inc. director was just granted 10,000 options - June 14, 2019

Lipocine Inc. director was just granted 10,000 options - June 14, 2019

Submission of Matters to a Vote of Security - June 12, 2019

Lipocine: 15 Targeted For Testosterone Replacement Therapy Annual Trx ~7M - May 28, 2019

Lipocine Inc.'s President and CEO just picked up 10,000 shares - May 28, 2019

Notice of exempt solicitation submitted by non-management - May 22, 2019

Lipocine: The Nasdaq Stock Market Llc Outstanding Shares - May 15, 2019

Lipocine Announces Tlando™ Nda Pdufa Action Date Of November 9, 2019 - May 14, 2019

Lipocine Inc. Just Filed Its Quarterly Report:  March 31, 2019 Amor... - May 8, 2019

Lipocine Announces First Quarter 2019 Financial And Operational Results - May 8, 2019

Current report, items 8.01 and 9.01 - May 1, 2019

Lipocine Inc. releases salary data. CEO sees compensation fall -8% - April 30, 2019

Lipocine: The International Liver Congress 2019 Presentation - April 11, 2019

Lipocine Seeks Injunction Against The Marketing Of Clarus Therapeutics’ Jatenzo® For Testosterone Replacement Therapy - April 3, 2019

Lipocine: 16 For Treatment Of Nash Cirrhosis - March 28, 2019

Lipocine Announces Abpm Labeling Study Results Consistent With Recently Approved Testosterone Replacement Therapy - March 27, 2019

Lipocine Late-Breaker Presentation At Easl Meeting To Detail Lpcn 1144 Mri-Pdff Based Clinical Results On Reduction Of Liver Fat And Key Serum Biomarkers - March 26, 2019

Lipocine: 5 Targeted For Testosterone Replacement Therapy - March 18, 2019

Lipocine’S Lpcn 1144 For Nash Demonstrates Substantial Fatty Liver - March 12, 2019

Lipocine: Therapeutic Potential Of Lpcn 1144 In Nafld/Nash - March 7, 2019

Lipocine Announces Financial And Operational Results For The Year Ended December 31, 2018 - March 6, 2019

Lipocine Inc. Just Filed Its Annual Report: (j) Earnings (Loss) ... - March 6, 2019

Lipocine Inc. Announces Fda Clearance Of Ind To Commence Phase 2 Study Of Lpcn 1144 In Biopsy Confirmed Nash Subjects - Feb. 14, 2019

Current report, items 8.01 and 9.01 - Jan. 28, 2019

Lipocine Files Ind To Evaluate Lpcn 1144 In Biopsy Confirmed Nash Subjects - Jan. 24, 2019

The Company made a presentation of LPCN 1144 data at the Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD Conference in Santa - Jan. 22, 2019

Lipocine’S Nash Therapy Candidate Achieves Meaningful Liver Fat Reduction Based On Interim Results - Jan. 17, 2019

Uspto Grants Priority Motion To Lipocine And Enters Judgment Against Clarus - Jan. 14, 2019

Current report, items 8.01 and 9.01 - Jan. 7, 2019

Lipocine: Conversion Assessment Of Tlando™ - Dec. 31, 2018

Lipocine Announces Lpcn 1144 Clinical Trial Results Selected For Presentation At 2019 Nash-Tag Conference - Dec. 21, 2018

Lipocine Announces Lpcn 1144 Mri-Pdff Clinical Results Selected For Presentation At Keystone Symposia On Integrated Pathways Of Disease In Nash And Nafld - Dec. 20, 2018

Lipocine Inc.'s EVP and CFO was just granted 190,000 options and restricted shares - Dec. 6, 2018

Lipocine Inc.'s President and CEO was just granted 440,000 options and restricted shares - Dec. 6, 2018

The Company will present data from several clinical trials of an oral prodrug of bioidentical - Nov. 9, 2018

Lipocine Announces Completion Of Enrollment In Lpcn 1144 Liver Imaging Study In Subjects At-Risk For Nash SALT LAKE CITY, UT - Nov. 5, 2018

Lipocine Announces Completion Of Enrollment In Ambulatory Blood Pressure Study For Tlando™ SALT LAKE CITY, UT - Nov. 1, 2018

Current report, items 8.01 and 9.01 - Oct. 1, 2018

Lipocine: Lpcn 1144 Competitive Biomarker Data Comparison - Aug. 29, 2018

Departure of Directors or Certain - Aug. 17, 2018

Securities to be offered to employees in employee benefit plans - Aug. 8, 2018

Current report, items 8.01 and 9.01 - Aug. 7, 2018

Lipocine Inc. Just Filed Its Quarterly Report: The following table ... - Aug. 7, 2018

Changes in Registrants Certifying - June 29, 2018

Lipocine Inc. director was just granted 20,000 options - June 28, 2018

Lipocine Inc. director was just granted 20,000 ownership of the company. - June 28, 2018

Lipocine Inc. director was just granted 20,000 options - June 28, 2018

Lipocine Inc. director was just granted 20,000 options - June 28, 2018

Departure of Directors or Certain - June 28, 2018

Submission of Matters to a Vote of Security - June 13, 2018

Lipocine Announces Dosing In Ambulatory Blood Pressure Study For Tlando™ SALT LAKE CITY, UT - June 7, 2018

Lipocine Inc. Just Filed Its Quarterly Report: (2) Earning... - May 7, 2018

Lipocine Announces Financial And Operational Results For The First Quarter Ended March 31, 2018 - May 7, 2018

Lipocine: Form, Schedule Or Registration Statement No Filing Party: Date Filed: PROXY STATEMENT SUPPLEMENT LIPOCINE INC. - May 4, 2018

Lipocine Inc. releases salary data. CEO sees compensation fall -39% - April 27, 2018

Lipocine: Men'S Health Franchise Testosterone Replacement Therapy (“Trt”) Women'S Health Preterm Birth (“Ptb”) Proprietary Drug Delivery Platform Significant Unmet Need In Both Therapeutic Areas 3 Uni - March 12, 2018

Lipocine Inc. Just Filed Its Annual Report: (15) Subseque... - March 12, 2018

Lipocine: Documents Incorporated By Reference - March 12, 2018

Lipocine Announces Settlement Of Securities Class Action Lawsuit SALT LAKE CITY, UT - Feb. 16, 2018

Koh, Bong just provided an update on share ownership of Lipocine Inc. - Feb. 14, 2018

Current report, items 8.01 and 9.01 - Feb. 13, 2018

Lipocine Announces $10 Million Loan And Security Agreement With Silicon Valley Bank SALT LAKE CITY, UT - Feb. 8, 2018

Invesco Ltd. just issued a filing suggesting it has sold all of its Lipocine Inc. - Feb. 6, 2018

Lipocine Announces Outcome Of Fda Advisory Committee Meeting For Tlando™, Testosterone Replacement Therapy In Adult Males With Hypogonadism - Jan. 10, 2018

Entry into a Material Definitive - Jan. 9, 2018

On January - Jan. 8, 2018

Royce & Associates, LP just provided an update on share ownership of Lipocine Inc. - Jan. 3, 2018

Lipocine Inc.'s Chief Commercial Officer just picked up 5,625 shares - Jan. 2, 2018

Lipocine Inc. director just picked up 937 shares - Jan. 2, 2018

CEO of Lipocine Inc. just picked up 9,000 shares - Jan. 2, 2018

Lipocine Inc.'s EVP and CFO just picked up 6,562 shares - Jan. 2, 2018

Lipocine Inc. director just picked up 1,250 shares - Jan. 2, 2018

Lipocine Inc. director just picked up 875 shares - Jan. 2, 2018

Lipocine Inc. director just picked up 1,250 shares - Jan. 2, 2018

Lipocine Inc.'s EVP and CFO was just granted 75,000 options - Dec. 6, 2017

CEO of Lipocine Inc. was just granted 150,000 options - Dec. 6, 2017

Lipocine Inc.'s EVP and Chief Commercial Offic was just granted 75,000 options - Dec. 6, 2017

Lipocine Inc. Just Received a Notice of Effectiveness - Nov. 21, 2017

Registration statement under Securities Act of 1933 - Nov. 17, 2017

Lipocine: U.S. Fda Extends Review For Tlando™; Advisory Committee Meeting Date Of January 10, 2018 Remains Unchanged SALT LAKE CITY, UT - Nov. 17, 2017

Lipocine: Men'S Health Franchise Testosterone Replacement Therapy (“Trt”) Women'S Health Preterm Birth (“Ptb”) Proprietary Drug Delivery Platform Significant Unmet Need In Both Therapeutic Areas 3 Uni - Nov. 8, 2017

Lipocine Announces Financial And Operational Results For The Third Quarter And Nine Months Ended September 30, 2017 - Nov. 8, 2017

Lipocine Inc. Just Filed Its Quarterly Report: (2) Earnings ... - Nov. 8, 2017

Lipocine: Dy48Wik8Sed(C\^"Cqx M.Gam&Ul;G,Z>#Tb861O8F4Z;G,Z;65T82\B('@Z>&Up=&L](D%D M;V)E(%A-4"!#;W)E(#4N,Buc,# Q(#8S+C$S.30S.2P@,C Q,"\P.2\R-Rtq M,Shs-Shr-B @(" @(" @(Cx*(" @/')D9Ci21$8@>&Ul;G,Z 6YT87 - Oct. 25, 2017

Lipocine: Fda Advisory Committee Scheduled To Review Tlando™ On January 10, 2018 SALT LAKE CITY, UT - Oct. 18, 2017

Registration statement under Securities Act of 1933 - Oct. 13, 2017

Lipocine: Men'S Health Franchise Testosterone Replacement Therapy (“Trt”) Women'S Health Preterm Birth (“Ptb”) Proprietary Drug Delivery Platform Significant Unmet Need In Both Therapeutic Areas 3 Uni - Sept. 25, 2017

Lipocine Announces Motions Decision By Uspto In Interference Against Clarus - Sept. 21, 2017

Lipocine Announces Fda Advisory Committee Meeting For Tlando™ SALT LAKE CITY, UT - Sept. 20, 2017

Lipocine: Men'S Health Franchise Testosterone Replacement Therapy (“Trt”) Women'S Health Preterm Birth (“Ptb”) Proprietary Drug Delivery Platform Significant Unmet Need In Both Therapeutic Areas 3 Uni - Sept. 8, 2017

Lipocine Announces Fda Acknowledgement Of Tlando™ (“Lpcn 1021”) Nda Resubmission; Pdufa Goal Date, - Aug. 14, 2017

Lipocine Resubmits Nda For Its Oral Testosterone Product Candidate, Lpcn 1021, For Treatment Of Hypogonadism - Aug. 9, 2017

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. VHCP Management, LLC 849,921 5.5 Dec. 31, 2016
2. Ameriprise Financial Inc 702,400 N/A March 31, 2019
3. Ameriprise Financial Inc 573,650 N/A June 30, 2019
4. VANGUARD GROUP INC 555,868 N/A June 30, 2019
5. RENAISSANCE TECHNOLOGIES LLC 495,659 N/A June 30, 2019
6. BlackRock Fund Advisors 465,599 N/A Sept. 30, 2016
7. BlackRock Institutional Trust Company, N.A. 365,851 N/A Dec. 31, 2016
8. Del Mar Asset Management, LP 330,683 N/A Sept. 30, 2014
9. GEODE CAPITAL MANAGEMENT, LLC 196,352 N/A June 30, 2019
10. DIMENSIONAL FUND ADVISORS LP 143,667 N/A June 30, 2019
11. Russell Frank Co/ 90,476 N/A Sept. 30, 2015
12. BlackRock Investment Management, LLC 62,520 N/A Dec. 31, 2016
13. MORGAN STANLEY 57,429 N/A Dec. 31, 2016
14. NORTHERN TRUST CORP 51,017 N/A June 30, 2018
15. NORTHERN TRUST CORP 50,817 N/A March 31, 2019
16. Knoll Capital Management, LP 50,000 0.1 June 30, 2019
17. CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 46,000 N/A June 30, 2019
18. NORTHERN TRUST CORP 43,416 N/A March 31, 2018
19. GROUP ONE TRADING, L.P. 41,140 N/A March 31, 2019
20. JPMORGAN CHASE & CO 22,616 N/A Sept. 30, 2017
21. SUSQUEHANNA INTERNATIONAL GROUP, LLP 22,257 N/A June 30, 2019
22. PANAGORA ASSET MANAGEMENT INC 22,218 N/A June 30, 2019
23. SUSQUEHANNA INTERNATIONAL GROUP, LLP 22,152 N/A June 30, 2019
24. Spark Investment Management LLC 17,700 N/A June 30, 2019
25. Geduld E E 15,000 N/A Dec. 31, 2016
26. State Street Corp 12,400 N/A June 30, 2019
27. LADENBURG THALMANN FINANCIAL SERVICES INC 10,828 N/A Sept. 30, 2017
28. BlackRock Advisors LLC 10,155 N/A Sept. 30, 2016
29. CITIGROUP INC 3,447 N/A Sept. 30, 2017
30. MEEDER ASSET MANAGEMENT INC 3,408 N/A June 30, 2019

Lipocine Inc. (LPCN)

140
 


Feedback